The Anticoagulation Market is projected to reach USD 31,696.59 million by 2027 at a CAGR of 7.80% during the forecast period. The global anticoagulation market is growing steadily due to the rising demand for anticoagulants, which creates lucrative growth opportunities for the number of players coming forward with new and better products. The value chain analysis of the anticoagulation market comprises four major components: research & development and designing, manufacturing the products, distribution & sales, and post-sales services.
Research &development start with conceptualizing, followed by design, then development, and lastly, testing. The R&D segment comprises 25-30% of the value chain. After the product designs are final, the manufacturing of the product starts. Manufacturing consists of 45-50% of the value chain. Then comes distribution and sales, which is essential for any industry
Top Growth Boosters
Escalating cases of heart attacks worldwide, on the backdrop of bad eating habits and soaring number of smokers and alcoholics, have widened the patient base for anticoagulants in recent years. Anticoagulation drugs are witnessing strong sales worldwide, but particularly in emerging countries, in view of the rising financial aid by the government and other authorities to upgrade medical facilities and service quality. Sensing the lucrative opportunities that lie in the anticoagulation market, most of the players are focusing on conducting exhaustive research & development activities, which is bolstering the number of pipeline drugs. This has ultimately had an excellent impact on the global industry.
The booming geriatric population worldwide has been favorable for the global market as well. This demography is significantly vulnerable to several chronic ailments, which fosters the need for anticoagulation drugs. Players active in this field are shouldering the financial burden of patients via programs, as a way to foster the awareness about anticoagulants. For example, Bristol-Myers Squibb is a well-known brand that provides financial assistance to patients with respect to buying medicines via its foundation. This program is primarily for patients from the United States.
The global Anticoagulation Reversal Agents is segmented into drug class, route of administration, disease indication, distribution channel, and region. The drug class segment has been further segmented into direct oral anticoagulants (DOACs), warfarin,vitamin K,and heparins&Low Molecular Weight Heparin (LMWH). The disease indication segment is further segmented into heart attacks,stroke, Deep Vein Thrombosis (DVT)/Pulmonary Embolism (PE), Mechanical Heart Valves (MHV), and others. The route of administration segment has been further segmented into oral, injectable, andothers.The distribution channel segment is segmented into retail pharmacies,hospital pharmacies, andonline pharmacies.
The global anticoagulation market, based on region, has been divided into North America, Europe, Asia-Pacific, and the Rest of the World.
The North American market accounted for the largest share in 2019 and is expected to increase at a CAGR of 8.20% during the forecast period. This is due to the rising prevalence of venous thromboembolism (VTE) and cardiovascular disorders, increased risk of a blood clot in various medical conditions, and the adoption of NOACs globally. According to a published article in PubMed in 2019, NOACs have emerged as promising alternatives to Vitamin K Antagonists (VKAs). However, there are some considerations and challenges to their introduction in developing countries.
Europe accounted for a market size of USD 5,205.37million in 2019 and is expected to grow at a CAGR of 7.26% during the forecast period. It has evolved as a prominent market with increased cardiovascular diseases and rising investments in R&D in the pharmaceutical sector. The region has considerable growth potentials that would help expand the global market in the coming years. However, stringent regulations set by various governments are hampering the market growth in the European region.
The anticoagulation market in Asia-Pacific has been segmented into China, India, Japan, South Korea, Australia, and the Rest of Asia-Pacific. Asia-Pacific is expected to showthe highest growth rate during the forecast period from 2020 to 2027. Factors such as an increasing patient population suffering from various chronic and acute diseases, rising prevalence of cardiovascular disease and VTE, developing economies, improving diagnosis rate, and growing demand for ideal therapeutics are anticipated to boost the market growth. Furthermore, continuous economic development with evolving healthcare infrastructure and improving healthcare awareness have further supported the market’s growth. However, increasing treatment expenditure for anticoagulant drugs is anticipated to hamper the market growth in the Asia-Pacific region.
The Rest of the World is segmented into the Middle East, Africa, and Latin America. The Middle East & Africa region market is expected to witness significant growth due to the increasing number of research companies and subsidiaries involved in R&D activities for anticoagulants. The rising prevalence of cardiovascular disorders in the region is also influencing the growth of the anticoagulation market.
Some of the key players operating in the anticoagulation market are Pfizer Inc (US), Sanofi (France), Novartis AG (Switzerland), GlaxoSmithKline plc (UK), Daiichi Sankyo Company, Limited, Inc. (Japan), Johnson & Johnson Services Inc (US), Boehringer Ingelheim International GmbH (Germany), Bristol-Myers Squibb Company (US), F. Hoffmann-La Roche Ltd (Switzerland), and Portola Pharmaceuticals, Inc (US).
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.
Market Research Future (part of Wantstats Research and Media Private Limited),
99 Hudson Street, 5Th Floor,
New York, New York 10013
United States of America
+1 628 258 0071
Email: [email protected]